Ardent Health Partners (NYSE:ARDT) Updates FY 2025 Earnings Guidance

Ardent Health Partners (NYSE:ARDT) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 1.730-2.010 for the period, compared to the consensus EPS estimate of 1.930. The company issued revenue guidance of $6.2 billion-$6.5 billion, compared to the consensus revenue estimate of $6.3 billion.

Ardent Health Partners Price Performance

Ardent Health Partners stock traded down $0.88 during mid-day trading on Friday, hitting $14.28. 224,874 shares of the company traded hands, compared to its average volume of 383,079. The company has a current ratio of 1.91, a quick ratio of 1.78 and a debt-to-equity ratio of 0.78. Ardent Health Partners has a one year low of $13.55 and a one year high of $20.72. The stock has a fifty day moving average price of $15.23 and a 200-day moving average price of $16.84.

Ardent Health Partners (NYSE:ARDT) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.81 EPS for the quarter, beating the consensus estimate of $0.50 by $0.31. The firm had revenue of $1.61 billion for the quarter, compared to the consensus estimate of $1.48 billion. Analysts forecast that Ardent Health Partners will post 1.23 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $23.00 price objective on shares of Ardent Health Partners in a research report on Thursday, November 14th. Truist Financial reduced their price target on Ardent Health Partners from $22.00 to $21.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Stephens reiterated an “overweight” rating and issued a $22.00 price objective on shares of Ardent Health Partners in a report on Thursday. Morgan Stanley reduced their target price on Ardent Health Partners from $23.50 to $22.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 21st. Finally, Leerink Partners upped their target price on Ardent Health Partners from $23.00 to $25.00 and gave the company an “outperform” rating in a report on Tuesday, November 12th. Two analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $21.36.

About Ardent Health Partners

Ardent Health Partners, Inc owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee.